BCR-ABL levels at 3 months from start of treatment in evaluable patients. Panels show BCR-ABL levels at 3 months from start of treatment overall (A) and by Sokal risk score at baseline (B) in patients treated with nilotinib 300 mg twice daily (n = 258), nilotinib 400 mg twice daily (n = 260), or imatinib 400 mg once daily (n = 264). Patients with unevaluable BCR-ABL transcript levels (n = 24 in the nilotinib 300 mg twice-daily arm, 21 in the nilotinib 400 mg twice-daily arm, and 19 in the imatinib arm) were excluded from the landmark analyses for the following reasons: atypical transcripts at baseline: nilotinib 300 mg twice daily (n = 5), nilotinib 400 mg twice daily (n = 1), and imatinib (n = 2); missing samples at 3 months: nilotinib 300 mg twice daily (n = 4), nilotinib 400 mg twice daily (n = 3), and imatinib (n = 5); or discontinued treatment by 3 months (3-month PCR analysis not performed): nilotinib 300 mg twice daily (n = 15, including 1 progression event), nilotinib 400 mg twice daily (n = 17), and imatinib (n = 12, including 1 progression event). INT, intermediate.